Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/11591
Title: HLA-matched sibling bone marrow transplantation for β-thalassemia major
Authors: Mitchell Sabloff
Mammen Chandy
Zhiwei Wang
Brent R. Logan
Ardeshir Ghavamzadeh
Chi Kong Li
Syed Mohammad Irfan
Christopher N. Bredeson
Morton J. Cowan
Robert Peter Gale
Gregory A. Hale
John Horan
Suradej Hongeng
Mary Eapen
Mark C. Walters
The Ottawa Hospital
Christian Medical College, Vellore
Medical College of Wisconsin
University of Tehran
Prince of Wales Hospital Hong Kong
National Institute of Blood Disease and Bone Marrow Transplantation
UCSF Medical Center
Celgene Corporation
All Children's Hospital St. Petersburg
Children's Healthcare of Atlanta at Egleston
Mahidol University
UCSF Benioff Children's Hospital Oakland
Keywords: Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine
Issue Date: 3-Feb-2011
Citation: Blood. Vol.117, No.5 (2011), 1745-1750
Abstract: We describe outcomes after human leukocyte antigen-matched sibling bone marrow transplantation (BMT) for 179 patients with β-thalassemia major. The median age at transplantation was 7 years and the median follow-up was 6 years. The distribution of Pesaro risk class I, II, and III categories was 2%, 42%, and 36%, respectively. The day 30 cumulative incidence of neutrophil recovery and day 100 platelet recovery were 90% and 86%, respectively. Seventeen patients had graft failure, which was fatal in 11. Six of 9 patients with graft failure are alive after a second transplantation. The day 100 probability of acute graft-versus-host disease and 5-year probability of chronic graft-versus-host disease was 38% and 13%, respectively. The 5-year probabilities of overall- and disease-free survival were 91% and 88%, respectively, for patients with Pesaro risk class II, and 64% and 62%, respectively, for Pesaro risk class III. In multivariate analysis, mortality risks were higher in patients 7 years of age and older and those with hepatomegaly before BMT. The leading causes of death were interstitial pneumonitis (n = 7), hemorrhage (n = 8), and veno-occlusive disease (n = 6). Proceeding to BMT in children younger than 7 years before development of end-organ damage, particularly in the liver, should improve results after BMT for β-thalassemia major. © 2011 by The American Society of Hematology.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79551639277&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/11591
ISSN: 15280020
00064971
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.